TCGA-A2-A0YC-01A-11R-A109-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 33
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- ESTROGEN_RESPONSE_EARLY+0.390
- PROTEIN_SECRETION+0.350
- INTERFERON_GAMMA_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.310
- ADIPOGENESIS+0.290
- ANGIOGENESIS+0.290
- UV_RESPONSE_DN+0.280
- ESTROGEN_RESPONSE_LATE+0.230
- MITOTIC_SPINDLE+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.450
- E2F_TARGETS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.260
- PANCREAS_BETA_CELLS-0.230
- MYC_TARGETS_V1-0.220
- NOTCH_SIGNALING-0.180
- KRAS_SIGNALING_DN-0.170
- MTORC1_SIGNALING-0.160
- ALLOGRAFT_REJECTION-0.130
- KRAS_SIGNALING_UP-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A10E-01A-21R-A10J-07 | — | B | 0.728 |
| 2 | TCGA-AN-A0XP-01A-11R-A109-07 | — | B | 0.690 |
| 3 | MNG385 | — | — | 0.684 |
| 4 | BS_V0Q1G94N | low-grade glioma | — | 0.681 |
| 5 | TCGA-AN-A0FF-01A-11R-A034-07 | — | B | 0.676 |
| 6 | BS_WFD0GE5X | EPN | Posterior Fossa EPN | 0.651 |
| 7 | TCGA-A2-A0EV-01A-11R-A034-07 | — | B | 0.650 |
| 8 | TCGA-UY-A9PA-01A-11R-A38B-07 | — | — | 0.648 |
| 9 | TCGA-44-6145-01A-11R-1755-07 | — | cohortA1 | 0.641 |
| 10 | MNG177 | — | — | 0.636 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |